About this trial
Endoscopic retrograde cholangiopancreatography (ERCP) is commonly used for the diagnosis and treatment of pancreatobiliary diseases. While Monitored Anesthesia Care (MAC) enhances the efficiency of ERCP, deep sedation introduces significant airway risks, particularly hypoxemia resulting from sedative-induced upper airway collapse. With reported hypoxemia rates ranging from 10% to 69%, and the potential for severe complications such as myocardial ischemia and neurological damage, effective airway management is paramount. Supraglottic oxygenation via oral transtracheal catheter provides a viable method for relieving obstruction and enabling positive pressure ventilation, serving as a less invasive alternative to tracheal intubation. Despite its proven utility in other settings, this technique has not yet been evaluated in the context of deeply sedated ERCP.
Eligibility criteria
Qualifiers
Age≥18years
The ASA classification ranges from I to III
Patients have signed the informed consent form
Patients scheduled to undergo sedated ERCP examination procedure
Disqualifiers
Severe cardiac dysfunction (<4 METs);
Diagnosed chronic obstructive pulmonary disease (COPD) or other acute/chronic pulmonary diseases requiring long-term/intermittent oxygen therapy;
Upper respiratory tract infections including oral, nasal or pharyngeal infections;
Fever (core temperature >37.5°C);
Trial design
Treatments tested in this trial
- The Supraglottic Oxygenation Via Oral Transtracheal Catheter Group
- The Regular Nasal Cannula